Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
diagnosis
|
| gptkbp:alternativeTo |
gptkb:Oncotype_DX
gptkb:MammaPrint gptkb:Prosigna |
| gptkbp:analyzes |
gptkb:Molecular_Grade_Index
gene expression HOXB13/IL17BR ratio |
| gptkbp:approvedBy |
gptkb:Centers_for_Medicare_&_Medicaid_Services
|
| gptkbp:developedBy |
gptkb:BioTheranostics
|
| gptkbp:firstDescribed |
2008
|
| https://www.w3.org/2000/01/rdf-schema#label |
Breast Cancer Index
|
| gptkbp:includes |
gptkb:NCCN_guidelines
gptkb:ASCO_guidelines |
| gptkbp:marketedAs |
gptkb:BioTheranostics
|
| gptkbp:notRecommendedFor |
gptkb:HER2-positive_breast_cancer
gptkb:triple-negative_breast_cancer |
| gptkbp:provides |
risk of late distant recurrence
prediction of benefit from extended tamoxifen therapy |
| gptkbp:type |
formalin-fixed paraffin-embedded tissue
genomic assay |
| gptkbp:used_in |
early-stage hormone receptor-positive breast cancer
|
| gptkbp:usedFor |
breast cancer prognosis
predicting benefit from extended endocrine therapy |
| gptkbp:bfsParent |
gptkb:Biotheranostics
|
| gptkbp:bfsLayer |
7
|